Back

Daraxonrasib Trial Reports Responses in Pancreatic Cancer

A combination of daraxonrasib, gemcitabine and nab-paclitaxel produced a confirmed objective response rate of 60.7% in a 61-patient group receiving first-line treatment for metastatic pancreatic adenocarcinoma, according to Revolution Medicines. The findings form part of the updated Phase 1/2 RMC-GI-102 results presented at the EORTC-NCI-AACR Symposium on November 20, 2026, in Barcelona, Spain.

The company's analysis used a September 28, 2026, cutoff, with median follow-up reaching 18.3 months. None of the 61 patients had previously received treatment for metastatic disease. For the confirmed objective response rate, the company reported a 95% confidence interval of 47.3% to 72.9%; complete responses accounted for 8.2% of patients.

Daraxonrasib is designed to disrupt signaling by active RAS, according to the symposium organizer. The organizer describes RAS as a system involved in cell-growth signaling that can stay abnormally active in pancreatic cancer. In the reported treatment schedule, Revolution Medicines said patients received daraxonrasib orally at 200 mg each day. Intravenous chemotherapy was given on treatment-cycle days 1 and 15, using gemcitabine at 1,000 mg/m² and nab-paclitaxel at 125 mg/m².

Revolution Medicines also reported disease control in 90.2% of the cohort. Responses lasted a median of 11.1 months, with a 95% confidence interval of 7.6 to 18.4 months. For progression-free survival, the median was 12.8 months and the corresponding confidence interval was 10.8 to 18.4 months. The company's estimate for overall survival at 12 months was 76.6%, with a 95% confidence interval of 63.7% to 85.4%.

On safety, the symposium organizer said common adverse effects included fatigue, diarrhea, rash and lower blood-cell counts. Side effects related to daraxonrasib resulted in treatment discontinuation for 5% of patients, according to the organizer.

A separate Phase 3 study, RASolute 303, remains ongoing, according to Revolution Medicines. For patients with untreated metastatic pancreatic adenocarcinoma, that trial is comparing three regimens: daraxonrasib by itself, daraxonrasib combined with gemcitabine and nab-paclitaxel, and the two chemotherapy drugs without daraxonrasib.

* This article is based on publicly available information at the time of writing.